TM Technologies, Inc.
Barcelona, Spain - Mobile World Congress 2024
BARCELONA, SPAIN / ACCESSWIRE / February 29, 2024 / TM Technologies has partnered with Switzerland's Quantum Resistant Cryptography, S.A. (QRC) to increase both the speed and security of wireless communications. QRC's cutting-edge encryption is nine orders of magnitude stronger than AES-256, providing unparalleled quantum resistance. The combination of TM Technologies' bandwidth-optimizing Cognitive Spectrum Optimization ("CSO") with QRC's best-of-class encryption is now capable of providing low-latency quantum-resistant communications at speeds that exceed current non-encrypted communications.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Logo for Header
The advent of quantum computing is widely understood to pose an imminent threat to the security of all conventionally encrypted information, including communications of passwords, transactions, and personal information.
The incorporation of QRC quantum-resistant encryption will initially be applied to three leading Transpositional Modulation use cases:
- Near Field Communications: Used commonly in point of sale from credit cards and mobile applications as well as in the hospitality and healthcare industries, the quantum-resistant QRC encryption combined with TM Technologies' CSO is estimated to exceed current NFC speeds by 13.5x.
- Satellite Communications: Whether geostationary, conventional LEO or LEO direct to device, TM + QRC offers a means to increase download speeds while greatly improving security.
- 5G / 6G: 3GPP-compatible and ORAN-compatible high-security use cases, such as in the enterprise, smart cities or law enforcement, can utilize this speed and security enhancement to stay ahead of emerging threats.
TM Technologies Director of Research and Development Dr. Scott Velasquez said, "Transpositional Modulation has existing security features that make it one of the most efficient and secure waveforms in existence, and our QRC partnership adds an important component of export-compliant quantum-resistant encryption that make sense for all customers interested in future-proofing their secure communications."
"TM Technologies' innovative solution has created dramatically faster contactless transactions," said Stiepan Kovac, founder and Group CEO of QRC. "Our advanced encryption adds the best security to this novel technology without negatively affecting the efficacy or speed. We are very proud of this novel collaboration."
About TM Technologies, Inc. www.tmtechnologies.com
TM Technologies is a privately held, independent technology research, development and intellectual property firm founded in 2013. With engineering and lab space in San Diego, California, and its administrative offices in Little Switzerland, North Carolina, TM provides software licenses and integrative engineering to customers in the fields of advanced wireless technologies, Near Field Communications and In-Band-Full-Duplex solutions.
About Quantum Resistant Cryptography, S.A. www.QRcrypto.ch
QRC provides forward-thinking encryption solutions that are energy-efficient, quantum-resistant, 5G/6G+-compatible and enable future-proof communications, public infrastructure, financial transactions, and private data protection. QRC's unique patented quantum-safe technology in 5G systems is the only solution recommended by the United Nations International Telecom Union (UN ITU-T).
Contact Information
Dan Hodges
CEO
info@tmtechnologies.com
(828) 330-4492
Related Images
SOURCE: TM Technologies
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
Accurate Background Partnering with Konfir to Provide Fast, Secure Instant Employment Verification in the United Kingdom5.12.2024 09:15:00 CET | Press release
IRVINE, CA / ACCESSWIRE / December 5, 2024 / Accurate Background, headquartered in Irvine, CA, and the largest privately held and minority-owned global provider of compliant background checks, drug and health screening, and workforce monitoring solutions, has announced a new partnership with Konfir, an innovative company providing employment verification technology in the UK. This collaboration will provide Accurate's clients access to Konfir's real-time verification tools via Accurate technology. Accurate's integration of Konfir's instant employment verification API will allow candidates to aggregate real-time data from multiple data sources including Payroll, HMRC, and Open Banking, streamlining screening processes and reducing time-to-hire. In addition, Accurate will now offer enhanced fraud mitigation tools through Konfir's suite of insights helping employers identify potential hiring risks more effectively. Kevin Stone, Sales & Marketing Director at Accurate, commented: "At Accura
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom